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Abstract  39 
Background: We aimed to derive and externally validate a 0/2h-algorithm using the 40 
high-sensitivity cardiac troponin I (hs-cTnI)-Access assay. 41 
Methods: We enrolled patients presenting to the emergency department with 42 
symptoms suggestive of acute myocardial infarction (AMI) in two prospective 43 
diagnostic studies using central adjudication. Two independent cardiologists 44 
adjudicated the final diagnosis including all available medical information including 45 
cardiac imaging. hs-cTnI-Access concentrations were measured at presentation and 46 
after 2h in a blinded fashion.  47 
Results: AMI was the adjudicated final diagnosis in 164/1131 (14.5%) patients in the 48 
derivation cohort. Rule-out by the hs-cTnI-Access 0/2h-algorithm was defined as 0h-49 
hs-cTnI-Access concentration <4ng/L in patients with an onset of chest pain >3h (direct 50 
rule-out), or a 0h-hs-cTnI-Access concentration <5ng/L and an absolute change within 51 
2h <5ng/L in all other patients. Derived thresholds for rule-in were a 0h-hs-cTnI-Access 52 
concentration ≥50ng/L (direct rule-in), or an absolute change within 2h ≥20ng/L. In the 53 
derivation cohort, these cut-offs ruled-out 55% of patients with a negative predictive 54 
value (NPV) of 99.8% (95%CI, 99.3-100), sensitivity of 99.4% (95%CI 96.5-99.9) and 55 
ruled-in 30% of patients with a positive predictive value (PPV) of 73% (95%CI, 66.1-56 
79). In the validation cohort, AMI was the adjudicated final diagnosis in 88/1280 (6.9%) 57 
patients. These cut-offs ruled-out 77.9% of patients with a NPV of 99.8% (95%CI, 99.3-58 
100), sensitivity of 97.7% (95%CI 92.0-99.7) and ruled-in 5.8% of patients with a PPV 59 
of 77% (95%CI, 65.8-86) in the validation cohort.  60 
Conclusions: Safety and efficacy of the l hs-cTnI-Access 0/2h-algorithm for triage 61 
towards rule-out or rule-in of AMI are very high. 62 
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Trial Registration: APACE: NCT00470587, ADAPT: ACTRN1261100106994, 63 
IMPACT: ACTRN12611000206921. 64 
 65 
Abbreviations 66 
ED – Emergency department 67 
AMI – Acute myocardial infarction 68 
ECG – Electrocardiography 69 
cTn – Cardiac troponin 70 
hs-cTn – High-sensitivity cardiac troponin 71 
eGFR – Estimated glomerular filtration rate 72 
NPV – Negative predictive value 73 
PPV – Positive predictive value 74 
IQR – Interquartile range 75 
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Introduction 86 
Patients with symptoms suggestive of an acute myocardial infarction (AMI) such as 87 
chest discomfort or angina pectoris, account for approximately 10% of all emergency 88 
department (ED) consultations worldwide(1) Early diagnosis of AMI is important for 89 
immediate initiation of appropriate, evidence-based therapy. For early rule-out and 90 
rule-in of AMI, electrocardiography (ECG) and cardiac troponin (cTn) form the 91 
diagnostic cornerstones and complement clinical assessment.(2–4) 92 
High-sensitivity cardiac troponin (hs-cTn) assays allow the precise 93 
measurement of cTn concentrations even in the normal range,(2) and have improved 94 
the diagnostic accuracy for AMI.(3,4) During the last decade, two hs-cTnT/I assays 95 
have been extensively investigated in large diagnostic studies, including the derivation 96 
and validation of safe and effective 0/1h-algorithms and 0/2h-algorithms(5–14) These 97 
rapid triage algorithms are recommended by the European Society of Cardiology 98 
(ESC) for routine clinical use with a class I recommendation. (7,15)  99 
Recently, the new hs-cTnI-Access assay was developed.(16–18) Here, we 100 
aimed to follow the ESC recommendations to derive and externally validate an assay-101 
specific 0/2h-algorithm. The algorithm incorporates hs-cTnI-Access concentrations at 102 
ED presentation and absolute 2h-changes for the very early triage of patients towards 103 
rule-out or rule-in of AMI. 104 
105 
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Materials and Methods 106 
Study design and population  107 
We enrolled adult patients presenting to the ED with suspected AMI in large 108 
prospective multicenter diagnostic studies carried out according to the principles of the 109 
Declaration of Helsinki and approved by the local ethics committees. Advantageous 110 
Predictors of Acute Coronary Syndrome Evaluation (APACE), an ongoing prospective 111 
international multicenter study with 12 centers in 5 countries aiming to advance the 112 
early diagnosis of AMI (ClinicalTrials.gov registry, number NCT00470587), was used 113 
as the derivation cohort.(3,19,20) Patients from two studies using similar inclusion and 114 
exclusion criteria were used as the external validation cohort: Accelerated Diagnostic 115 
Protocol to Assess patients with chest Pain symptoms using contemporary Troponins 116 
as the only biomarker (ADAPT) and Improved Assessment of Chest Pain Trial 117 
(IMPACT). ADAPT was a multicenter, diagnostic study enrolling patients between 118 
November 2007 and February 2011 in two study centers in Australia and New Zealand 119 
(16,21,22). Only the Australian data were available for this study. IMPACT was an 120 
intervention trial conducted at the same Australian site between February 2011 and 121 
March 2014.(23) Patients with ST segment elevation myocardial infarction (STEMI) 122 
have been excluded from analysis in all cohorts. 123 
 124 
Clinical Assessment 125 
In both the derivation and validation cohorts we included unselected patients 126 
presenting to the ED with acute chest discomfort. All patients underwent a clinical 127 
assessment that included standardized and detailed medical history incorporating 128 
assessment of chest pain characteristics, vital signs, physical examination, 12-lead 129 
electrocardiogram (ECG), continuous ECG rhythm monitoring, pulse oximetry, 130 
standard blood tests, and chest radiography and echocardiography if indicated.  131 
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Detailed methodical descriptions in both cohorts including study design, eligibility 132 
criteria and study population, adjudication of final diagnoses, follow-up and clinical 133 
endpoints are shown in the online Supplement including online Supplemental Table 134 
1. 135 
 The authors designed the study, gathered, analyzed and reported the data 136 
according to the STARD guidelines for studies of diagnostic accuracy(24) (online 137 
Supplemental Table 2), vouched for the data and analysis, wrote the paper, and made 138 
the decision to submit it for publication. The sponsors had no role in the design of the 139 
study, the analysis of the data, the preparation of the manuscript, or the decision to 140 
submit the manuscript for publication. 141 
 142 
Investigational hs-cTn measurements 143 
Blood samples for determination of hs-cTnI-Access, hs-cTnI-Architect and hs-cTnT-144 
Elecsys were collected into tubes containing lithium heparin plasma or serum, 145 
respectively. Additional samples were collected at 1, 2, 3, and 6h after presentation in 146 
the derivation cohort and after 2 and/or 6 to 12h in the validation cohort. Serial sampling 147 
was discontinued when a patient was discharged or transferred to the catheter 148 
laboratory for acute treatment. After centrifugation, samples were frozen at -80°C until 149 
assayed in a blinded fashion in a dedicated core laboratory. 150 
The hs-cTnI-Access assay (ACCESS hs-cTnI, Beckman Coulter) is a paramagnetic 151 
particle, chemiluminescent immunoassay for high sensitivity quantitative determination 152 
of cTnI concentrations in human serum and plasma using the Access Immunoassay 153 
Systems.(15–17) The hs-cTnI-Access assay has an overall 99th percentile 154 
concentration of 18ng/L (women: 12ng/L, men: 20ng/L) with a corresponding co-155 
efficient of variation (CV) of <10%. Limit of blank (LoB) and limit of detection (LoD) 156 
have been determined to be 1.7ng/L and 2.3ng/L.  157 
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The hs-cTnT-Elecsys assay (Elecsys 2010 high-sensitivity troponin T, Roche 158 
Diagnostics) has a 99th percentile concentration of 14ng/L with a corresponding CV of 159 
10% at 13ng/L.(2) LoB and LoD have been determined to be 3ng/L and 5ng/L.(2) The 160 
hs-cTnI-Architect assay (ARCHITECT STAT high-sensitivity troponin I, Abbott 161 
Laboratories) has a 99th percentile concentration of 26ng/L with a corresponding CV of 162 
<5% and a LoD of 1.9ng/L.(25–27) Estimated glomerular filtration rate (eGFR) was 163 
calculated using the abbreviated Modification of Diet in Renal Disease formula.(28) 164 
 165 
Reference Standard: Adjudicated Final Diagnosis 166 
AMI was defined and cTn concentrations interpreted as recommended in current 167 
guidelines.(29–31) In brief, AMI was diagnosed when there was evidence of 168 
myocardial necrosis with a significant rise and/or fall in a clinical setting consistent with 169 
myocardial ischemia. Patients with AMI were further subdivided into type 1 AMI 170 
(primary coronary events) and type 2 AMI (ischemia due to increased demand or 171 
decreased supply, for example tachyarrhythmia or hypertensive crisis).(29,32) In 172 
APACE the adjudication of final diagnoses was performed centrally in the core lab 173 
(University Hospital Basel) for all patients incorporating concentrations of (hs)-cTn. 174 
More specifically, two independent cardiologists not directly involved in patient care 175 
reviewed all available medical records (including patient history, physical examination, 176 
results of laboratory testing including hs-cTnT concentrations, radiologic testing, ECG, 177 
echocardiography, cardiac exercise test, lesion severity and morphology in coronary 178 
angiography, discharge summary) pertaining to the patient from the time of ED 179 
presentation to 90-day follow-up (APACE) and to 30-day follow-up (ADAPT and 180 
Impact). Detailed information about adjudication of final diagnoses are shown in the 181 
online Supplement. 182 
 183 
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Derivation and validation of the hs-cTnI-Access 0/2h-algorithm  184 
We combined hs-cTnI-Access concentrations at ED presentation and absolute 2h-185 
changes to achieve predefined performance characteristics using the same 186 
methodology as applied in the derivation of the established hs-cTnT/I 0/2h-algorithms 187 
(14,15,32,33) (online Supplemental Figure 1). Derived thresholds for rule-out were 188 
selected to allow for a minimal sensitivity and negative predictive value (NPV) of 99.5% 189 
and sensitivity of 99.0%. Derived thresholds for rule-in were obtained based on a 190 
classification and regression tree (CART) analysis targeting a minimal positive 191 
predictive value (PPV) of 70%. Nodes in the CART tree were constrained to have a 192 
minimal number of cases of 20 in parent and child nodes. If a predefined target 193 
performance was missed in the derivation sample using the CART-derived thresholds, 194 
thresholds were changed stepwise until the predefined performance was fulfilled. A 195 
more detailed explanation for derivation and validation of the algorithm is given within 196 
the online supplement. 197 
 The hs-cTnI-Access 0/2h-algorithm was developed in the derivation cohort in all 198 
patients with available hs-cTnI-Access measurements at ED presentation and after 2h. 199 
The algorithm was then externally validated in the validation cohort, and directly 200 
compared with the established 0/2h-algorithms.  201 
 202 
Follow-up and statistical analysis 203 
Clinical follow-up and statistical analysis are described in detail in the Online 204 
Supplement.  205 
 206 
 207 
Results 208 
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Characteristics of patients and final adjudicated diagnosis 209 
Patient flow for eligible patients for this analysis within the derivation and validation 210 
cohort is shown in online Supplemental Figure 1A and 1B. Baseline characteristics 211 
of the patients in the derivation cohort (n=1131) and the validation cohort (n=1280) are 212 
shown in Tables 1 and 2. Thirty-nine percent and 81% of patients presented to the ED 213 
within the first three hours after chest pain onset in both cohorts, respectively. The 214 
adjudicated final diagnosis in the derivation cohort was AMI in 164/1131 patients 215 
(14.5%), and in 88/1280 patients (6.9%) in the validation cohort. 216 
 217 
Concentrations of hs-cTnI-Access at presentation according to final diagnoses 218 
Concentrations of hs-cTnI at presentation and after 2 hours were significantly higher 219 
in patients with AMI compared to those with other final diagnoses (online 220 
Supplemental Figure 3A and 3B and Supplemental Figure 4).  221 
 222 
Derivation of the hs-cTnI-Access 0/2h-algorithm  223 
Derived thresholds for rule-out of AMI were defined as either a hs-cTnI-Access 224 
concentration at presentation <4ng/L in patients with an onset of chest pain >3h (direct 225 
rule-out) or as a hs-cTnI-Access concentration at presentation <5ng/L and an absolute 226 
change within 2h <5ng/L in all other patients (online Supplemental Figure 2). Derived 227 
thresholds for rule-in of AMI were defined as either a hs-cTnI-Access concentration at 228 
presentation ≥50ng/L (direct rule-in) or an absolute change within 2h ≥20ng/L. Patients 229 
fulfilling neither of the above criteria for rule-out or for rule-in were classified as 230 
observe. The hs-cTnI-Access 0/2h-algorithm classified 620 (55%) patients as rule-out, 231 
333 (29%) as rule-in and 178 (16%) patients to observe (Figure 1A). The algorithm 232 
achieved a NPV of 99.8% (95%CI, 99.1-100) and a sensitivity of 99.4% (95%CI, 96.5-233 
99.9) for rule-out (Table 3). PPV and specificity for rule-in were 73% (95%CI, 66.1-234 
79.0) and 95% (95%CI, 93.5-96.2), respectively. Overall, the hs-cTnI-Access 0/2h-235 
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algorithm allowed a definite triage (either rule-out or rule-in) in 798/1131 patients 236 
(71%).  237 
 238 
External validation of the hs-cTnI-Access 0/2h-algorithm 239 
Applying the derived cut-off criteria to the independent validation cohort, 997/1280 240 
patients (77.9%) could be classified as rule-out with a corresponding NPV of 99.8% 241 
(95%CI, 99.3-100) and sensitivity of 97.7% (95%CI, 92.0-99.7; Figure 1B, Table 3). 242 
The 0/2h-algorithm classified 74/1280 patients (5.8%) as rule-in with a corresponding 243 
PPV of 77.0% (95%CI, 65.8-86.0) and a specificity of 98.6% (95%CI, 97.7-99.2). 244 
Overall, the hs-cTnI-Access 0/2h-algorithm allowed to triage (either rule-out or rule-in) 245 
1071/1280 patients (84%).  246 
 247 
Direct comparison with established 0/2h-algorithms  248 
Overall, the diagnostic performance of the hs-cTnI-Access 0/2h-algorithm was similar 249 
to that of the hs-cTnT-Elecsys 0/2h-algorithm and the hs-cTnI-Architect 0/2h-algorithm 250 
within the derivation and the validation cohorts. (online Supplemental Figure 5A and 251 
5B).  252 
 253 
Performance of the hs-cTnI-Access 0/2h-algorithm in predefined subgroups 254 
The performance of the hs-cTnI-Access 0/2h- algorithm in five predefined subgroups 255 
including early presenters was very good and comparable to that in the overall cohort 256 
(online Supplemental Figure 6A and 6B). 257 
 258 
Prognostic performance of the hs-cTnI-Access 0/2h-algorithm  259 
Within the derivation cohort median follow-up time was 735 days (IQR, 410-772) 260 
with 9 deaths occurring within 30 days and 60 deaths within two years. Cumulative 30-261 
day survival rates were 99.7%, 98.5% and 97.1% (standard error 0.2, 0.7 and 1.2 262 
respectively; log-rank, P=0.001) in the rule-out, observe and rule-in group, 263 
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respectively. At 2 years, cumulative survival rates were 98.2%, 91.1% and 89.6%, 264 
within the rule-out, rule-in and observe group, respectively (standard error 0.6, 1,9 and 265 
2.3, respectively; log-rank, P<0.001; Figure 2A).  266 
Within the validation cohort the median follow-up time was 365 days (IQR, 365-267 
365) with 2 deaths occurring within 30 days and 13 deaths within one year. Cumulative 268 
30-day survival rates were 100%, 99.4% and 98.2% (standard error 0, 0.6 and 0.2, 269 
respectively log-rank, P=0.005) in the rule-out, observe and rule-in group, respectively. 270 
After one-year, cumulative survival rates were 99.9%, 95.2% and 92.9% within the 271 
rule-out, observe, and rule-in group, respectively (standard error 0.1, 1.6 and 3.4, 272 
respectively; log-rank, P<0.001; Figure 2B).  273 
 274 
Discussion  275 
We derived and validated a 2h-algorithm for the hs-cTnI-Access assay in three large, 276 
well-characterized prospective diagnostic cohorts using central adjudication of AMI. 277 
Institutions using this assay will be able to apply this attractive rapid protocol to triage 278 
a high volume of patients presenting to ED’s with symptoms suggestive of AMI.(13,14) 279 
We report six major findings:  280 
 First, the derived hs-cTnI-Access 0/2h-algorithm provided a very high (>99.5%) 281 
NPV in both the derivation and validation cohorts, while sensitivity was slightly lower 282 
in the validation cohort (97.7%) as compared to the derivation cohort (99.4%). The high 283 
safety of this approach is further highlighted by the fact that both type 1 and type 2 AMI 284 
were included in this analysis and that among more than 2400 patients enrolled, the 285 
hs-cTnI-Access 0/2h-algorithm incorrectly triaged only one patient with type 1 AMI. 286 
Still, as the point estimate for sensitivity in patients triaged towards rule-out was lower 287 
than aimed for, further studies with an even higher number of patients with AMI are 288 
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required. Second, the PPV and specificity for AMI of patients triaged towards rule-in 289 
was high enough (>70% and >95%, respectively) to justify early coronary angiography 290 
and admission to a monitored unit, particularly as most non-AMI patients in the rule-in 291 
group still have conditions that require coronary angiography for diagnostic purposes 292 
including myocarditis and takotsubo syndrome. Third, the overall efficacy of the hs-293 
cTnI-Access 0/2h-algorithm was very high by assigning more than 70% of patients to 294 
either rule-out or rule-in, with less than 30% of patients remaining in the observe zone. 295 
Fourth, overall, the performance of the 0/2h-algorithm for hs-cTnI-Access was 296 
comparable to that of the established 0/2h-algorithms for hs-cTnT-Elecsys and hs-297 
cTnI-Architect, and also similar to their performance in previous studies.(33)(14)(16) 298 
Fifth, the performance of the hs-cTnI-Access 0/2h-algorithm was also very good in five 299 
predefined subgroups including early presenters. Sixth, survival in patients triaged 300 
towards rule-out by the 0/2h-algorithm was very high in both cohorts, further 301 
underscoring the convenient and safety of early discharge from the ED for most 302 
patients classified as rule-out, with further outpatient management as clinically 303 
appropriate.  304 
These findings corroborate and extend previous pilot studies with hs-cTnI-305 
Access,(15–17) and may have important clinical implications, as they will allow 306 
institutions utilizing the Beckman Coulter platform, to introduce the hs-cTnI-Access 307 
0/2h-algorithm for management of patients with suspected AMI. For some sites, 308 
adoption of clinical practice guidelines without the logistic challenges and costs of 309 
introducing additional analyzers will be a major benefit. (29,30,32)  310 
Local institution and physician preferences, as well as patient flow characteristics, will 311 
determine whether performing the second hs-cTn measurement at 1h (for the 0/1h-312 
algorithm) or at 2h (for the 0/2h-algorithm) is preferable. Overall, the performance 313 
characteristics of the new hs-cTnI-Access 0/2h-algorithm were comparable to that of 314 
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the recently developed hs-cTnI-Access 0/1h-algorithm, which allowed triage of 60% of 315 
patients towards rule-out with a sensitivity of 98.9% and 15% of patients towards ruled 316 
in with a specificity of 95.9% in the respective validation cohort.(18) Greenslade and 317 
colleagues reported a high sensitivity of 99% and NPV of 99.8% with 34% ruled-out 318 
using a single cut-off strategy with <2 ng/L (LOD strategy) for the hs-cTnI Access 319 
Assay. A cutoff of <6 ng/L enabled 78.8% of patients to be ruled out on presentation, 320 
with a sensitivity of 93.9% and a NPV of 99.5%(16) The present study used a 321 
combination of 0h and 2h hs-cTnI concentrations. A cut-off of 4 ng/L at presentation 322 
together with a chest pain onset of >3h revealed the best performance for direct rule-323 
out. Simplicity and higher efficacy may favor these hs-cTn-only algorithms versus other 324 
well-validated algorithms also including formal risk scores. (18,21,34–37) The present 325 
findings extend and corroborate previous work with other hs-cTnT/I assays. 326 
(7,11,38,39) Accordingly, the same concepts and caveats apply to the most 327 
appropriate clinical use of any of the hs-cTnT/I assays and their respective 0/1h or 328 
0/2h-algorithms in the early diagnosis of AMI. (7,13,14,35) First, these algorithms 329 
should only be applied after ST elevation MI has been ruled-out by the ECG performed 330 
at presentation. Second, although the hs-cTnI-Access 0/2h-algorithm had a very high 331 
NPV for AMI, the algorithm should always be used in conjunction with all other clinical 332 
information, including a detailed assessment of chest pain characteristics, physical 333 
examination, and the ECG. Additional measurements of hs-cTnI (for example at 3h) 334 
are advised whenever the patient is in the observe group, remains symptomatic, or 335 
where clinical judgment still argues in favor of AMI. These will help to detect the rare 336 
but existing phenomenon of delayed release of hs-cTn into the circulation, particularly 337 
in early presenters.(32) It will also help to detect uncommon but possible errors in the 338 
handling of the clinical blood samples. Third, not all patients triaged towards rule-out 339 
of AMI are appropriate candidates for early discharge from the ED. Fourth, patients 340 
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triaged towards rule-in AMI in general are candidates for consideration of early 341 
coronary angiography. About 75% of patients triaged towards rule-in will be found to 342 
have AMI. Most of the remaining patients in the rule-in zone may still benefit from 343 
coronary angiography for diagnostic and possible therapeutic purposes as common 344 
differential diagnoses including takotsubo syndrome, myocarditis, and unstable 345 
angina.(32)  346 
Some limitations merit consideration when interpreting these findings. First, this 347 
study was conducted in ED patients with symptoms suggestive of AMI. Further studies 348 
are required to quantify the utility of this 0/2h-algorithm in patients with either a higher 349 
pre-test probability (e.g., in a coronary care unit setting) or in patients with a lower pre-350 
test probability (e.g., in a general practice setting) for AMI, as well as in the inherently 351 
challenging group of critically ill patients. Second, the data presented were obtained 352 
from prospective observational diagnostic studies. Prospective studies applying the 353 
diagnostic algorithm in clinical decision-making are warranted. Third, not all patients 354 
with acute chest pain had a second set of laboratory measurements at 2h and later. 355 
The most common reasons for missing blood samples were logistics issues in the ED 356 
that precluded blood draw around the 2h-window. This limitation is inherent to studies 357 
enrolling consecutive patients and is very unlikely to have affected the main findings of 358 
the present study. Additionally, for the reference standard, not all patients had 359 
measurements of hs-cTn at 3-6h after presentation. In all remaining patients for 360 
adjudication of final diagnoses the ESC hs-cTnT 0/1h algorithm has been used. 361 
Fourth, although we used the most stringent methodology to adjudicate the presence 362 
or absence of AMI including central adjudication by experienced cardiologists, we still 363 
may have misclassified a small number of patients.(30) This invariably would have led 364 
to an underestimation of the true diagnostic accuracy of the 0/2h-algorithm. Fifth, 365 
although all laboratory procedures were performed according to stringent standardized 366 
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operating procedures, human error in the handling of the study specific blood samples 367 
may have occurred in a small number of samples leading incorrect to results pertaining 368 
to the individual patient. This again would have led to an underestimation of the true 369 
diagnostic accuracy of the 0/2h-algorithm. In fact, this error might well have occurred 370 
in all three AMI patients presumably missed by the 0/2h-algorithm as not only hs-cTnI-371 
Access, but all hs-cTnT/I concentrations measured from the study specific blood 372 
samples were in the low normal range. Sixth, our findings are specific to the hs-cTnI-373 
Access assay. The derived 0/2h-algorithm cannot be generalized to other hs-cTnI 374 
assays. Seventh, we cannot generalize our findings to patients with terminal kidney 375 
failure requiring dialysis, since they were excluded in the derivation cohort.  376 
In conclusion, using a simple algorithm incorporating hs-cTnI values at 377 
presentation and absolute changes within the first 2 hours, a safe rule-out or accurate 378 
rule-in of AMI could be performed in the vast majority of patients presenting with chest 379 
pain. The use of this algorithm seems to be safe and highly efficacious. It may 380 
substantially shorten the time needed for rule-out and rule-in of AMI. About one quarter 381 
of chest pain patients will remain in the observe zone and continue to require more 382 
prolonged monitoring and serial hs-cTnI testing at 3-6h. Further prospective studies 383 
are inevitable to validate these findings  384 
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 622 
Numbers are presented as numbers (%) or medians (IQR). CPO denotes chest pain 623 
onset; AMI denotes acute myocardial infarction; ECG denotes electrocardiogram; 624 
ACEIs denotes angiotensin-converting-enzyme inhibitors. ARBs denotes angiotensin 625 
receptor blockers. 626 
Table 1 Baseline characteristics derivation cohort 
 
All patients 
(n=1131) 
AMI  
(n=164) 
No AMI  
(n=967) 
Age – y  61 (49-74) 71 (60-81) 59 (47-72) 
Female gender  
Time since cpo – hours 
359 (32) 
5 (2-12) 
43 (26) 
4 (2-12) 
316 (33) 
5 (2-12) 
Early presenters (within 3h after CPO) 439 (39%) 72 (44%) 367 (38%) 
Risk factors     
Hypertension 689 (61) 117 (71) 572 (59) 
Hypercholesterolemia 580 (51) 116 (71) 464 (48) 
Diabetes 199 (18) 45 (28) 154 (16) 
Current smoking 279 (25) 39 (24) 240 (25) 
History of smoking 432 (38) 76 (46) 356 (37) 
History     
Coronary artery disease 386 (34) 73 (45) 313 (32) 
Previous MI 281 (25) 59 (36) 222 (23) 
Previous revascularization 329 (29) 63 (38) 266 (28) 
Peripheral artery disease 62 (5.5) 24 (15) 38 (3.9) 
Previous stroke 78 (6.9) 13 (7.9) 65 (6.7) 
ECG findings     
Left bundle branch block 35 (3.1) 4 (2.4) 31 (3.3) 
ST-segment depression 78 (6.9) 33 (20) 45 (4.7) 
T-wave inversion 86 (7.6) 23 (14) 63 (6.5) 
No significant ECG abnormalities 912 (81) 100 (61) 812 (84) 
Body mass index – kg/m2 
Laboratory findings 
27 (24-30) 26 (24-29) 27 (24-30) 
Creatinine clearance, mL/min/m2 84 (70-100) 76 (60-94) 85 (71-101) 
Chronic medication     
Aspirin 400 (35) 79 (48) 321 (33) 
Vitamin K antagonists 135 (12) 25 (15) 110 (11) 
B-blockers 388 (34) 64 (39) 324 (34) 
Statins 431 (38) 76 (46) 355 (37) 
ACEIs/ARBs 450 (40) 84 (51) 366 (38) 
Calcium antagonists 185 (16) 40 (24) 145 (15) 
Nitrates 
 
132 (12) 34 (21) 98 (10) 
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 627 
Numbers are presented as numbers (%) or medians (IQR). CPO denotes chest pain 628 
onset; AMI denotes acute myocardial infarction; ECG denotes electrocardiogram; 629 
ACEIs denotes angiotensin-converting-enzyme inhibitors. ARBs denotes angiotensin 630 
receptor blockers. 631 
Table 2 Baseline characteristics validation cohort 
 All patients 
(n=1280) 
AMI  
(n=88) 
No AMI  
(n=1192) 
Age – y  51 (43-62) 62 (53-75) 51 (43-61) 
Male sex  769 (60.1%) 59 (67.0%) 710 (59.6%) 
Median Time since cpo – hours  2.1 (1.2-4.2) 2.1 (1.1-4.2) 2.1 (1.2-4.2) 
Early presenters (within 3h after CPO) 1035 (80.9%) 72 (81.8%) 963 (80.8%) 
Risk factors     
Hypertension 558 (43.6%) 49 (55.7%) 509 (42.7%) 
Hypercholesterolemia 542 (42.3%) 49 (55.7%) 493 (41.4%) 
Diabetes 164 (12.8%) 18 (20.5%) 146 (12.3%) 
Current smoking 354 (27.7%) 22 (25.0%) 332 (27.9%) 
History of smoking 434 (33.9%) 38 (43.2%) 396 (33.2%) 
History     
Coronary artery disease 221 (17.3%) 36 (40.9%) 185 (15.5%) 
Previous MI 183 (14.3%) 30 (34.1%) 153 (12.8%) 
Previous revascularization 159 (12.4%) 24 (27.3%) 135 (11.3%) 
Peripheral artery disease 18 (1.4%) 7 (8.0%) 11 (0.9%) 
Previous stroke 78 (6.1%) 9 (10.2%) 69 (5.8%) 
ECG findings     
Left bundle branch block 20 (1.6%) 4 (4.6%) 16 (1.3%) 
New Ischaemia on ECG 37 (2.9%) 17 (19.5%) 20 (1.7%) 
ECG normal or not diagnostic of 
ischaemia 
1059 (82.9%) 50 (57.5%) 1009 (84.7%) 
Body mass index – kg/m2 
Laboratory findings 
28.3 (25.0-32.8) 28.0 (23.5-31.9) 28.3 (25.0-32.9) 
eGFR 92 (78-106) 79 (56-98) 93 (79-107) 
Chronic medication     
Aspirin 264 (20.6%) 30 (34.1%) 234 (19.6%) 
Warfarin 51 (4.0%) 6 (6.8%) 45 (3.8%) 
B-blockers 210 (16.4%) 29 (33.0%) 181 (15.2%) 
Statins 322 (25.2%) 34 (38.6%) 288 (24.2%) 
ACE Inhibitors 191 (14.9%) 16 (18.2%) 175 (14.7%) 
Calcium antagonists 101 (7.9%) 11 (12.5%) 90 (7.6%) 
Nitrates 
 
89 (7.0%) 15 (17.1%) 74 (6.2%) 
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 Table 3 – Patients with an Adjudicated Diagnosis of AMI missed by the hs-cTnI-Access 0/2h-algorithm in both cohorts  
 
Age Sex Time 
from 
CPO 
to 
first 
study 
blood 
draw, 
h 
Time from 
CPO/Peak to 
presentation, 
h 
History 
of CAD 
hs-cTnT Elecsys# (ng/L; 
peak value underlined)  
99th percentile 14ng/L 
hs-cTnT Architect (ng/L; 
peak value underlined)  
99th percentile 26.2ng/L 
hs-cTnI Access (ng/L; 
peak value underlined) 
Accu cTnI# (ng/L; peak 
value underlined)  99th 
percentile 40ng/L 
ST-
depression 
T-
inversion 
Clinical 
discharge 
diagnosis 
PCI 
performed 
CABG 
performed 
0h 1h 2h 4-14h 0h 1h 2h 4-14h   
                  
 
79* 
 
female 
 
1 
 
1 
 
Yes 
 
18 
3.9 
 
 
19 
5.8 
 
22 
7 
 
24 
- 
 
2.6 
- 
 
3.3 
- 
 
4.2 
- 
 
- 
- 
 
Yes 
 
No 
 
Arrhythmia 
 
No 
 
No 
64+ Male 9 9 Yes 4.7 
1.3 
- 
- 
4.9 
1.9 
- 
- 
2.1 
110 
- 
- 
2.5 
130 
- 
130 
No No Arrhythmia No No 
63+ Male 2 2 No - 
2.3 
- 
- 
- 
5 
- 
- 
3.2 
90 
- 
- 
5.4 
92 
- 
100 
No No T1 
NSTEMI 
Yes No 
*missed in hs-cTnI 0/1h-algorithm derivation cohort; +missed in hs-cTnI 0/1h-algorithm validation cohort 633 
CPO denotes chest pain onset; CAD denotes coronary artery disease; CABG denotes coronary artery bypass grafting; PCI denotes 634 
percutaneous coronary intervention 635 
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#hs-cTnT in the derivation cohort and Accu TnI in the validation cohort were measured as part of routine clinical practice onsite at the 636 
time of patient presentation. All other hs-cTnT/I measurements were performed from study specific samples at a later time point after a 637 
freeze/thaw cycle.  638 
 639 
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Figure Legends  
 
 
 
 
Delta 2h│ denotes absolute (unsigned) change of high-sensitivity cardiac troponin I 
within 2 hours; NSTEMI denotes non-ST-elevation myocardial infarction; NPV denotes 
negative predictive value; Sens. denotes sensitivity; PPV denotes positive predictive 
value; Spec. denotes specificity  
 
Figure 1 Performance of the high-sensitivity cardiac troponin I Access 0/2h-algorithm in the A) derivation and B) validation cohorts 
30 
 
 
 
 
 
 
 
 
 
 
Figure 2 
Short-term and long-term Kaplan-Meier survival curves of patients 
classified according to the high-sensitivity cardiac troponin I 
Access 0/2h-algorithm for A) derivation and B) validation cohorts 
